8.50
price down icon7.91%   -0.73
 
loading

Bluebird Bio Inc Borsa (BLUE) Ultime notizie

pulisher
Dec 20, 2024

bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Gene Therapy For Rare Disease Market Overall Study Report - openPR

Dec 20, 2024
pulisher
Dec 18, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Gene Therapy Market Huge Growth in Future Scope 2024-2031 | - openPR

Dec 17, 2024
pulisher
Dec 16, 2024

Baird cuts bluebird bio price target on near-term dilution By Investing.com - Investing.com Canada

Dec 16, 2024
pulisher
Dec 16, 2024

bluebird bio (NASDAQ:BLUE) Shares Up 15.3%Time to Buy? - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Baird cuts bluebird bio price target on near-term dilution - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Cell and Gene Therapy Drug Delivery Devices Market to Witness - openPR

Dec 16, 2024
pulisher
Dec 15, 2024

Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 15, 2024

Bluebird Bio's SWOT analysis: gene therapy firm's stock faces cash crunch - Investing.com

Dec 15, 2024
pulisher
Dec 13, 2024

bluebird bio (NASDAQ:BLUE) Shares Down 13.4%Time to Sell? - MarketBeat

Dec 13, 2024
pulisher
Dec 13, 2024

Bluebird Bio presents long-term data on LYFGENIA gene therapy for SCD - MSN

Dec 13, 2024
pulisher
Dec 13, 2024

Bluebird bio CEO Andrew Obenshain sells $405 in stock By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 13, 2024

Cell and Gene Therapy Market is Dazzling Worldwide and Forecast - openPR

Dec 13, 2024
pulisher
Dec 12, 2024

Bluebird bio CEO Andrew Obenshain sells $405 in stock - Investing.com India

Dec 12, 2024
pulisher
Dec 12, 2024

Growing Demand and Trends of Advanced Cell Therapy - openPR

Dec 12, 2024
pulisher
Dec 12, 2024

bluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.com - MarketBeat

Dec 12, 2024
pulisher
Dec 09, 2024

Bluebird bio Gets Nasdaq Noncompliance Notice - Marketscreener.com

Dec 09, 2024
pulisher
Dec 08, 2024

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire

Dec 08, 2024
pulisher
Dec 08, 2024

BLUEbluebird bio, Inc. Latest Stock News & Market Updates - StockTitan

Dec 08, 2024
pulisher
Dec 07, 2024

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult H - Yahoo Finance

Dec 07, 2024
pulisher
Dec 04, 2024

CMS enters agreement with Vertex, bluebird to improve access to gene therapies - Reuters

Dec 04, 2024
pulisher
Dec 04, 2024

bluebird bio announces 1-for-20 reverse stock split; shares tumble - MSN

Dec 04, 2024
pulisher
Dec 04, 2024

Bluebird Bio announces 1-for-20 reverse stock split - TipRanks

Dec 04, 2024
pulisher
Dec 04, 2024

bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire

Dec 04, 2024
pulisher
Dec 04, 2024

FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program - Benzinga

Dec 04, 2024
pulisher
Dec 04, 2024

BLUE (bluebird bio) 3-Year FCF Growth Rate : 34.80% (As of Sep. 2024) - GuruFocus.com

Dec 04, 2024
pulisher
Dec 04, 2024

Bluebird and Vertex's sickle cell gene therapies to kick off new Medicaid access model - Endpoints News

Dec 04, 2024
pulisher
Dec 04, 2024

CMS rolls out new payment model for Vertex, bluebird gene therapies (NASDAQ:BLUE) - Seeking Alpha

Dec 04, 2024
pulisher
Dec 04, 2024

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model - Business Wire

Dec 04, 2024
pulisher
Dec 04, 2024

bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com - MarketBeat

Dec 04, 2024
pulisher
Dec 02, 2024

Gene Therapy And Secondary Malignancies: Integration Site Analysis Can Only Be Part Of The Answer - News & Insights

Dec 02, 2024
pulisher
Dec 02, 2024

FDA considers 'regulatory action' for bluebird's Skysona after blood cancer reports - FiercePharma

Dec 02, 2024
pulisher
Dec 02, 2024

Bluebird’s Gene Therapy Skysona Under FDA Safety Probe for Hematologic Malignancies - BioSpace

Dec 02, 2024
pulisher
Nov 29, 2024

Gene Therapy: Lyfgenia Voucher Denial Puts Sickle Cell Treatment At Risk, Bluebird Bio Says - News & Insights

Nov 29, 2024
pulisher
Nov 29, 2024

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy - Yahoo Finance

Nov 29, 2024
pulisher
Nov 28, 2024

FDA investigating safety risks of bluebird's Skysona - MSN

Nov 28, 2024
pulisher
Nov 27, 2024

FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action - Reuters

Nov 27, 2024
pulisher
Nov 27, 2024

FDA investigating safety risks of bluebird's Skysona (NASDAQ:BLUE) - Seeking Alpha

Nov 27, 2024
pulisher
Nov 26, 2024

bluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 results - MSN

Nov 26, 2024
pulisher
Nov 23, 2024

bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Nov 23, 2024
pulisher
Nov 22, 2024

Adrenoleukodystrophy Treatment Market Global Share, Trends, - openPR

Nov 22, 2024
pulisher
Nov 21, 2024

Bluebird Bio's SWOT analysis: gene therapy firm faces cash crunch amid launch - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

bluebird bio says seeking more cash to achieve cash flow break-even - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace

Nov 18, 2024
pulisher
Nov 18, 2024

Adoptive Cell Therapy Market Industry Insights: Market Size, - openPR

Nov 18, 2024
pulisher
Nov 18, 2024

StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

B of A Securities Downgrades bluebird bio (BLUE) - MSN

Nov 17, 2024
pulisher
Nov 16, 2024

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 16, 2024
pulisher
Nov 16, 2024

bluebird bio downgraded by Bank of America, shares tumble - Proactive Investors Australia

Nov 16, 2024
pulisher
Nov 15, 2024

Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus - MSN

Nov 15, 2024
pulisher
Nov 15, 2024

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - AOL

Nov 15, 2024
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Capitalizzazione:     |  Volume (24 ore):